Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Jan 28;63(3):251-8.
doi: 10.1016/j.jacc.2013.09.039. Epub 2013 Oct 23.

Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease)

Affiliations
Comparative Study

Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease)

Robert J Mentz et al. J Am Coll Cardiol. .

Abstract

Objectives: This study investigated the characteristics and outcomes of patients with heart failure with preserved ejection fraction (HFpEF) and angina pectoris (AP).

Background: AP is a predictor of adverse events in patients with heart failure with reduced EF. The implications of AP in HFpEF are unknown.

Methods: We analyzed HFpEF patients (EF ≥50%) who underwent coronary angiography at Duke University Medical Center from 2000 through 2010 with and without AP in the previous 6 weeks. Time to first event was examined using Kaplan-Meier methods for the primary endpoint of death/myocardial infarction (MI)/revascularization/stroke (i.e., major adverse cardiac events [MACE]) and secondary endpoints of death/MI/revascularization, death/MI/stroke, death/MI, death, and cardiovascular death/cardiovascular hospitalization.

Results: In the Duke Databank, 3,517 patients met criteria for inclusion and 1,402 (40%) had AP. Those with AP were older with more comorbidities and prior revascularization compared with non-AP patients. AP patients more often received beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and statins (all p < 0.05). In unadjusted analysis, AP patients had increased MACE and death/MI/revascularization (both p < 0.001), lower rates of death and death/MI (both p < 0.05), and similar rates of death/MI/stroke and cardiovascular death/cardiovascular hospitalization (both p > 0.1). After multivariable adjustment, those with AP remained at increased risk for MACE (hazard ratio [HR]: 1.30, 95% confidence interval [CI]: 1.17 to 1.45) and death/MI/revascularization (HR: 1.29, 95% CI: 1.15 to 1.43), but they were at similar risk for other endpoints (p > 0.06).

Conclusions: AP in HFpEF patients with a history of coronary artery disease is common despite medical therapy and is independently associated with increased MACE due to revascularization with similar risk of death, MI, and hospitalization.

Keywords: AP; CI; DDCD; Duke Databank for Cardiovascular Disease; EF; HF; HFpEF; HR; IQR; KM; Kaplan-Meier; MACE; MI; NYHA; New York Heart Association; angina pectoris; confidence interval; ejection fraction; hazard ratio; heart failure; heart failure with preserved ejection fraction; interquartile range; major adverse cardiac events; myocardial infarction; outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients included in this analysis. Abbreviation: AIDS=acquired immunodeficiency syndrome.
Figure 2
Figure 2
Adjusted time-to-event plot for death, myocardial infarction, revascularization or stroke in heart failure with preserved ejection fraction patients with vs. without angina pectoris*. *Adjusted for variables listed in Table 3 footnote.
Figure 3
Figure 3
Adjusted time-to-event plot for death or myocardial infarction in heart failure with preserved ejection fraction patients with vs. without angina pectoris*. *Adjusted for variables listed in Table 3 footnote.
Figure 4
Figure 4
Adjusted time-to-event plot for death in heart failure with preserved ejection fraction patients with vs. without angina pectoris*. *Adjusted for variables listed in Table 3 footnote.
Figure 5
Figure 5
Adjusted time-to-event plot for cardiovascular death, or cardiovascular hospitalization in heart failure with preserved ejection fraction patients with vs. without angina pectoris*. *Adjusted for variables listed in Table 3 footnote.

Similar articles

Cited by

References

    1. Fraker TD, Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50:2264–2274. - PubMed
    1. Mentz RJ, Fiuzat M, Shaw LK, et al. Comparison of Clinical characteristics and long-term outcomes of patients with ischemic cardiomyopathy with versus without angina pectoris (from the Duke Databank for Cardiovascular Disease) Am J Cardiol. 2012;109:1272–1277. - PubMed
    1. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124:e540–e543. - PubMed
    1. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126:65–75. - PubMed
    1. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) Eur Heart J. 1996;17:76–81. - PubMed

Publication types

MeSH terms